Results 131 to 140 of about 1,686,414 (204)

A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial. [PDF]

Nat Med
Ploquin A, Mason RD, Holman LA, Happe M, Widge AT, Novik L, Ortega-Villa AM, Yamshchikov GV, Gordon IJ, Ola A, Arthur A, Costner PJM, Mendoza F, Saunders J, Wang X, Whalen WR, Utoh J, Cunningham J, Loftus LN, Heimann A, Korzeniwsky K, Andrew SF, Lamb E, Shyam Sunder S, Thompson A, McDonald M, Foulds KE, Sullivan NJ, Bahorich J, Coates EE, Loomis RJ, Graham BS, Bok K, Himansu S, Leav B, Dempsey W, Beigel JH, Roederer M, Dropulic LK, VRC 322 study team.   +39 more
europepmc   +1 more source

Evaluation of the Effects of COVID-19 Infection and COVID-19 mRNA Vaccine on Ovarian Reserve. [PDF]

J Clin Med
Basibuyuk Z, Cebi Basibuyuk C, Okumus S, Oncul M, Ocal KP.   +4 more
europepmc   +1 more source

Enhanced mRNA vaccine combined with immune checkpoint blockade efficiently suppresses tumor growth and metastasis. [PDF]

J Nanobiotechnology
Zhang Y, Ma X, Jin D, Liu S, Song T, Du S, Liu Z, Lin J.   +7 more
europepmc   +1 more source

CpG 1018 augments mRNA vaccine-induced anti-tumor immunity by potentiating CD8+ T cell responses. [PDF]

Mol Ther Oncol
Li Y, Nakkala JR, Akter L, Kang X, Song Y, VanLuinen E, Chen X.   +6 more
europepmc   +1 more source

Integrative bioinformatics approach to the mRNA vaccine development for the human papillomavirus using the capsid protein. [PDF]

Biol Direct
He S, Zubair A, Ahmad F, Shahani MY, Zeng L, Afghan N.   +5 more
europepmc   +1 more source

Seasonal influenza mRNA vaccine induces stronger innate and comparable or better adaptive responses than licensed inactivated vaccines. [PDF]

NPJ Vaccines
Bermúdez-Méndez E, Lenart K, Arcoverde Cerveira R, Engstrand O, Hellgren F, Cagigi A, Ols S, Jasny E, Reinhardt A, Petsch B, Loré K.   +10 more
europepmc   +1 more source

Preclinical evaluation of a multi-epitope mRNA vaccine platform for broad and durable SARS-CoV-2 protection. [PDF]

Front Immunol
Marcos-Villar L, Perdiguero B, Sin L, Álvarez E, Flores S, Casasnovas JM, Pons T, Sorzano COS, Del Hoyo D, Lapuhs P, Alonso MJ, Esteban M, Gómez CE.   +12 more
europepmc   +1 more source

Design and in silico evaluation of an mRNA vaccine against HTLV-1 using AI-driven reverse vaccinology approaches. [PDF]

PLoS One
Seifi N, Nezafat N, Hajizade MS, Negahdaripour M.   +3 more
europepmc   +1 more source

A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma.

Blood
Dutta D, Liu J, Wen K, Ray A, Salatino A, Liu X, Gulla A, Hideshima T, Song Y, Anderson KC.   +9 more
europepmc   +1 more source

One-component ionizable amphiphilic Janus dendrimers as a delivery platform for efficient mRNA vaccine development. [PDF]

Sci Adv
Ona NA, Zhang D, Lindesmith LC, Park WJ, Meshanni JA, Berkihiser S, Vasserman JA, Toshtzar S, Moore NC, Williams B, Nakagawa B, Baboo I, Pan L, Cheng W, Mercado-López X, Bonilla-Acosta W, Brewer-Jensen PD, Zweigart MR, Reyes YI, Mallory ML, May SR, Zhou Y, Percec V, Baric RS, Li Y, Weissman D, Atochina-Vasserman EN.   +26 more
europepmc   +1 more source